Kornimate/medical-research-clean huggingface dataset:
the short-term effects of instrument-based mobilization compared with manual mobilization for low back pain: a randomized clinicaltrial

Conditions: Low Back Pain, Mechanical

Summary: objectives: to investigate the effectiveness of instrument-based mobilization compared with manual mobilization in patients with non-specific low back pain (nlbp), in terms of spinal muscle activation, decrease in pain, and improvement in range of motion (rom). design: randomized clinical trial, double blind. participants and interventions: a total of 66 participants with localized nlbp will be divided into 2 groups matched for sex, age, and body mass index. the intervention group will receive central postero-anterior mobilization with a force of 150 n through physiotherapy instrument mobilization at the level of pain in the lumbar spine. the control group will receive central postero-anterior grade iii mobilization through the pisiform grip method at the level of pain in the lumbar spine. main outcome measures: measurements will be taken before the intervention, after the 1st session, after the 6th session, and at 4 weeks follow-up. rehabilitative ultrasound imaging will be done to identify lumbar multifidus (lm) activation through the measurement of muscle thickness at the level of l5-l4 vertebrae, during rest and lower-extremity movement. each participant will self-rate the pain intensity in the lumbar spine according to the numeric pain rating scale (nprs). the pressure-pain threshold (ppt) will be measured using an algometer. lumbar rom will be measured using a dual inclinometer method in flexion and extension. the results will be compared between the intervention and control groups through mixed analysis of variance for lm thickness, lumbar rom, ppt, and nprs.


Eligibility criteria:
inclusion criteria: * age 20-59 years (commonly affected age range), bmi 18.5-30 kg/m2 (normal to overweight), localized nlbp, pain duration \<12 months, and pain score ≥3/10 on the nprs. exclusion criteria: * history of spinal surgery, significant previous back trauma, spinal or lower-extremity deformities, lbp associated with peripheral neurological symptoms (paraesthesia, anaesthesia, signs of nerve root compression), neurological diseases, systemic diseases (diabetes mellitus, rheumatoid arthritis), and any contraindication to manual therapy (spinal instability, healing fracture, dislocations, pregnancy in women).
national tunisian registry of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: a non-interventional, national longitudinal study of atrial fibrillation performed with 91 cardiologists.

the nature-af study is carried out in tunisia at cardiology consultations in hospitals and in the liberal sector. a total of 91 cardiologists participate in the selection of patients as investigators. the study is a longitudinal non-interventional registry of atrial fibrillation. the data collected are managed by the dacima clinical suite® platform, which complies with international standards: fda 21 cfr part 11 (food and drug administration 21 code of federal regulations part 11), hippa (health insurance portability and accountability act), ich (international conference on harmonisation), meddra (medical dictionary for regulatory activities). the dacima clinical suite® platform allows to track the data entered, check for inconsistencies and missing data, and schedule monitoring visits. a steering committee is set up to monitor patient inclusions, verify data sources, perform audit trails and prepare the statistical analysis plan for the study.

Eligibility criteria:
inclusion criteria: * at least one episode of atrial fibrillation, documented on a 12-lead ecg and / or a rhythmic holter (duration of the episode: 30 seconds or more) * recent atrial fibrillation diagnosed for less than a year * regular monitoring every 3 months is ensured * informed, read and signed consent exclusion criteria: * estimated life expectancy at less than 12 months * transient atrial fibrillation due to reversible cause (eg acute myocardial infarction, following cardiac surgery, acute alcohol intoxication, hyperthyroidism, pulmonary embolism or other acute pulmonary disease, pericarditis, myocarditis, hydro-electrolyte disorder, metabolic disorder) * cardiac surgery ≤ 3 months * atrial flutter isolated without atrial fibrillation * mental disorders * ongoing anticoagulation for reasons other than atrial fibrillation

Keywords: atrial fibrillation anticoagulation stroke vitamin k antagonist cardioversion inr (international normalized ratio)
real-world clinical patterns of care and outcomes among afme mrcc patients receiving sunitinib as first line therapy.

Conditions: Metastatic Renal Cell Carcinoma

Summary: optimise is designed to provide knowledge regarding the use of sunitinib as 1st line treatment and 2nd line treatment selected (sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related qol in the real life setting.

optimise study objectives are dual and aim primarily to increase the knowledge regarding the outcomes from sunitinib use on one hand; and outcomes from the combined sunitinib-2nd line sequence on the other hand in real life clinical practice. this will be addressed in many countries across afme and in individual country cohorts to understand specificities and differences in use and outcomes

Eligibility criteria:
* inclusion criteria: 1. patients being treated with su as 1st line treatment according to the approved therapeutic indication. 2. histologically confirmed diagnosis of mrcc (clear cell rcc as well as nonclear cell rcc) with measurable disease according to recist 1.1 3. evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. exclusion criteria: 1. patients being treated with cytokines or any other treatment other than su in 1st line setting 2. patients presenting with a known hypersensitivity to su or its metabolites will not be included in the study per the label.

Keywords: sunitinib metastatic renal cell carcinoma africa middle east
efficacy and safety of cinitapride tablets in the treatment of mild to moderate functional dyspepsia

Conditions: Dyspepsia

Summary: the purpose of this study is to compare cinitapride tablets with domperidone tablets (motilium), and to evaluate the efficacy and safety of cinitapride tablets in the treatment of mild to moderate functional dyspepsia.


Eligibility criteria:
inclusion: 1. aged between 18\~65 years, both males and females; 2. patients with symptoms of mild to moderate functional dyspepsia; 3. symptoms related to dyspepsia were developed 6 months ago and early satiety or/and discomfort after meal were developed in the past 3 months; 4. gastrointestinal malignancy, peptic ulcer, liver, gallbladder and pancreas diseases were excluded through gastroscopy, b-ultrasonography and laboratory examination within 4 weeks prior to administration (endoscopy results considered to be clinically unrelated will not be excluded, such as small hiatal hernia and chronic nonatrophic pangastritis); 5. patient has signed informed consent form. exclusion criteria 1. patients with gastroesophageal reflux and/or irritable bowel syndrome; 2. acid regurgitation more than once per week; 3. previously received abdominal surgery (except appendectomy and herniorrhaphy); 4. a history of gastric or duodenal ulcer; 5. patients with depression and anxiety neurosis; 6. patients with arrhythmia; 7. qtc more than 0.5s; 8. hepatic and renal insufficiency: ast or/and alt equal to or above 1.5 times of the upper normal limit; cr above the upper normal limit; 9. pathological lactorrhea; 10. patients with alcohol abuse (daily alcohol intake more than 40g), drug dependence or neuropsychiatric disorders that are difficult to control, as well as others who are not appropriate to participate in a drug trial; 11. pregnant or lactating women; 12. patients who require other therapy to change gastrointestinal mobility; 13. patients who are participating or participated in other drug clinical trial within 3 months prior to entry; 14. known to be allergic to cinitapride; patients who are considered by investigators to be inappropriate to participate.

Keywords: cinitapride efficacy safety mild to moderate functional dyspepsia
weigh easy: simplifying home weight monitoring for infants

Conditions: Cleft Lip and Palate

Summary: this single-site, experimental, pilot study in infants identified from 0 - 3 months of age who present to the cleft and craniofacial clinic with a cleft lip and/or palate will compare weight outcomes of infants who used the weigh easy system to monitor weight and historical infants whose weights were monitored without the weigh easy system.

patients will be recruited at the earliest possible visit to the cleft and craniofacial clinic. at this visit, families will complete the consent process. after consent is obtained, the study team will ensure that the family is signed up for the patient portal and will provide a demonstration of how to safely obtain a weight using the weigh easy scale and the infant's car seat. in addition to the luggage scale, a handout will also be sent home with the family, including instructions and safety tips for weighing their infant and instructions for submitting a weight via the patient portal. families will be asked to submit a weight, obtained with the weigh easy scale, via the weigh easy eclipboard message on a weekly basis for 3 months. three months after the family is enrolled onto the study, the family will be provided the parental satisfaction survey to complete. this will occur at a clinic visit, in the event that a standard of care visit occurs within the window for the visit. if a clinic visit is unavailable, the surveys will be emailed to the family and three reminders will be sent if the survey is not completed in a timely manner.

Eligibility criteria:
prospective group: inclusion criteria: * newborn patient ≤ 12 weeks old * referred to children's mercy hospital multidisciplinary cleft team from december 1, 2019 - november 30, 2020 * with a diagnosis of cleft lip and/or cleft palate * male or female infant of any ethnic background exclusion criteria: * infant with secondary major birth defect such as heart or abdominal wall defect in addition to cleft condition * infant who is placed in foster care prior to or during the applicable study period * patient parents unable to complete an electronic survey. * patient parents unable to speak and read spanish or english. retrospective group: inclusion criteria: * newborn patient ≤ 12 weeks old * referred to children's mercy hospital multidisciplinary cleft team from january 1, 2016 to june 30, 2019 * with a diagnosis of cleft lip and/or cleft palate * male or female infant of any ethnic background exclusion criteria: * infant with secondary major birth defect such as heart or abdominal wall defect in addition to cleft condition

Keywords: weight monitoring
effect of dolutegravir compared with darunavir/cobicistat on the severity of neuropsychiatric effects al 12 weeks in antirretroviral treatment-naive adults.

Conditions: HIV; Insomnia; Anxiety

Summary: this clinical trial aimed at evaluating changes in neuropsychiatric scales for depression, anxiety, insomnia, and sleep quality in people living with hiv (plhiv) who initiate antiretroviral therapy (art) with a regimen of dolutegravir (dtg) or darunavir/cobicistat (drv/c), both combined with tenofovir disoproxil fumarate/emtricitabine (tdf/ftc).

this clinical trial aims to evaluate changes in neuropsychiatric scale (nps) scores among mexican men living with hiv who present baseline nps symptoms and are naïve to antiretroviral therapy (art). participants will initiate either a dolutegravir (dtg)-based regimen or a darunavir/cobicistat (drv/c)-based regimen, both combined with tenofovir disoproxil fumarate/emtricitabine (tdf/ftc). all patients will undergo a psychiatric evaluation prior to art initiation. treatment discontinuation will be considered for participants experiencing an exacerbation of nps symptoms associated with grade ≥2 adverse events. nps scores will be assessed and compared at weeks 4 and 12.

Eligibility criteria:
inclusion criteria: * patients living with hiv not experienced to art * age ≥ 18 years. * egfr \>60 ml/min * beneficiaries of the mexican social security institute treated at the "la raza" national medical center * patients with a baseline isi scale score: ≥8-14 points * patients with a baseline phq-9 scale score: 5-9 points * patients with a baseline hads-a scale score: 8-10 points * patients with a baseline hads-d scale score: 8-10 points * patients with a baseline pittsburgh scale score: 5-7 points. exclusion criteria: * patients with use of antidepressants/anxiolytics prior to starting art * any contraindication for the use of second generation insti or ip art regimen * coinfection with hepatitis c virus * known resistance mutations to any of the components of both treatment regimens.

Keywords: insti hiv dolutegravir darunavir suicide depression anxiety
predictive clinical and biological parameters in breast cancer

Conditions: Breast Cancer

Summary: research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation


Eligibility criteria:
inclusion criteria: * breast cancer * age \> 18 * signed informed consent exclusion criteria: * emergency

Keywords: breast cancer
cardiac arrhythmias in epilepsy: the carelink-study

Conditions: Epilepsy; Asystole; Cardiac Arrhythmias

Summary: patients with difficult-to-treat epilepsy ("refractory epilepsy") are at high risk of sudden death: sudden unexpected death in epilepsy (sudep). cardiac arrhythmias are one of the possible causes of sudep. when monitoring in the hospital setting, the frequency of cardiac arrhythmias in people with epilepsy is low: 0,4%. however, when a subcutaneous implantable device (reveal xt) is used to monitor heart rhythm continuously for an extended period of time, the frequency of clinically relevant arrhythmias appeared much higher in two small observational studies (n=19): 6-20%. the aim of this study is to analyze the frequency and underlying mechanism of cardiac arrhythmias in a larger group of 50 people with refractory epilepsy with reveal xt. in the future, this may help us to identify those epilepsy patients at high risk of cardiac arrhythmias, so that we can timely institute preventive measures (e.g. pacemaker implantation).


Eligibility criteria:
inclusion criteria: * drug-resistant focal epilepsy: failure of adequate trials of two tolerated and appropriately chosen and used antiepileptic drug (aed) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom \[16\] * ≥ 1 complex partial and/or generalized tonic clonic seizure/month as indicated by history taking * if female, not pregnant * aged 18 to 60 years * able to undergo the study procedure as judged by the treating physician. exclusion criteria: * clinical suspicion of seizure-induced asystole (e.g. seizures with sudden flaccid falls) * reveal implantation (either present or in the past) * known clinical relevant structural cardiac disease * hereditary syndromes that increase the risk of cardiomyopathy (e.g. marfan's disease) * ecg findings suggestive of arrhythmias without proper cardiac evaluation to in- or exclude this possibility. according to european society of cardiology (esc) guidelines on syncope the following ecg findings will be used: bifascicular block and other intraventricular conduction abnormalities, asymptomatic inappropriate sinus bradycardia (\<50 bpm), sinoatrial block or sinus pause ≥3s in the absence of negative chronotropic medications, non-sustained vt, pre-exited qrs complexes, prolonged or short qt interval, brugada pattern, pattern suggestive of arrhythmogenic right ventricular cardiomyopathy. * pacemaker * use of beta blockers or other anti-arrhythmic/anti-arrhythmogenic medication * previous diagnosis of psychogenic non-epileptic seizures * patients who live alone and are not able to recall their seizures
the effect of reablement service of long-term care on physical mobility and quality of life in disable people

Conditions: Reablement; Home Rehabilitation

Summary: the long-term care 2.0 policy has been launched at 2017 by taiwanese government to respond the rate of aging population reached to14% and estimated to 20% in 2025, becoming a "super-aged society" in taiwan. as aging society, the ratio of chronic disease and disability has reasonably raised. the home reablement and care of this policy are not only to prevent and delay disability but provide daily care for the elderly who needed. as the implementation of the policy, there is still insufficient research to investigate and compare the effects on physical mobility and quality of life among the individual after using these different types of the service. therefore, the aim of the study is to compare the effects on physical function and quality of life of the frail and disabled individual with and without receiving the home reablement services. the participants will be enrolled from the long-term care service units registered in local government at hualien county, taiwan. the recruited participants will be assigned to two groups in a convenient method (receiving and non-receiving the home reablement service). all participants will be assessed by a professional physical therapist at three time points, before the reablement, at 1-3 months after receiving the reablement, then follow-up after 3 months


Eligibility criteria:
inclusion criteria: * aged from 50-90 years old * be able to follow the command and cooperate with the assessor * the disability grade level 2 to 8 according to the grading with long-term care case-mix system, approximately to 20 to 80 of barthel index score. * receiving the reablement services at least 3 times/a set. exclusion criteria: * using the outpatient rehabilitation service during the study period * transferring or delivering to institution * re-admission to hospital during using the service
doveegene/wise genomics: diagnosing ovarian and endometrial cancer early using genomics

Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Endometrial Cancer; Ovarian Cancer; Screening; Safety; Reduced Mortality; Reduced Morbidity; Early Diagnosis

Summary: this study aims to develop and validate a test for detecting ovarian and endometrial cancers early. it relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. a saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). a machine learning classifier is then used to discriminate between cancer and benign disease.

for women in high-income countries, ovarian/fallopian tube and endometrial cancers are within the top four cancers in terms of incidence, death and healthcare expenditure. the deaths associated with these cancers are largely caused by stage iii/iv disease, for which cure rates have not changed in three decades, despite escalating costs of treatment. attempts at early detection have been ineffective in reducing mortality, because the high-grade subtypes, which account for the majority of deaths, metastasize while the primary cancer is still small, has not caused symptoms, and is undetectable by imaging or blood tumour markers. in recent years, the recognition that somatic mutations are early steps in carcinogenesis has led to a shift from tests such as imaging and non-specific blood tumour markers to technology that detects cancer-associated mutations in cervical, uterine, or blood samples. several dna-tagging technologies have been shown to be capable of identifying small amount of cancer dna among thousands of normal cells, the proverbial needle in a haystack. this investigation aims to develop and validate a high-sensitivity capture using a panel of genes involved in ovarian and endometrial carcinogenesis, low-pass whole genome sequencing, coupled with a machine-learning derived classifier for discriminating cancer from benign gynecologic disease prevalent in peri/post-menopausal women.

Eligibility criteria:
case inclusion: * subjects should have suspected or confirmed cancer of the upper genital tract. * participant will undergo surgery for tumour removal. control inclusion: • subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.

Keywords: genomics somatic mutations genetic mutations high-grade serous cancer ovarian cancer endometrial cancer dna tagging
phase ii study of concurrent lenvatinib and radiotherapy for advanced hcc

Conditions: Hepatocellular Carcinoma; Radiotherapy; Lenvatinib

Summary: this is a single-arm, open-label study performed at our hospital, patients with progression hepatocellular carcinoma (hcc) met inclusion criteria will be enrolled. patients received oral lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) before local radiotherapy 8 weeks, large lesions were treated with imrt for 40-60gy / 20-30f. combined therapy will be taken until unacceptable treatment-related toxicities occurred or disease progression.


Eligibility criteria:
inclusion criteria: 1. patients had an hcc diagnosis confirmed either histologically or clinically according to the chinese society of clinical oncology guidelines for primary liver cancer 2019 version； 2. aged ≥18 years and \<80 years； 3. ecog 0-1; 4. live-gtv volume \> 700ml; 5. bclc stage c, hcc with portal vein or hepatic vein tumor thrombosis or lymph node involved (ln involved can be included one treatment planning); 6. estimated life expectancy should be more than 3 months; 7. patients with lung and / or bone metastases can be enrolled if those metastases couldn't effect the patients' life and quality of life within 3 months; 8. child-pugh score a5,a6,b7; 9. liver function: alt is less than 1.5 times of the upper limit of normal; alt is less than 0.5 times of the upper limit of normal, ast can be less than 6 times of the upper limit of normal, excluding the elevation of ast caused by heart infarction; alt is 0.5 to 1.5 times of the upper limit of normal, ast is less than 1.5 times of the upper limit of normal; 10. ecg examination showed no obvious abnormality, no obvious cardiac dysfunction; 11. renal function: cre and bun were within 1.5 times of the upper limit of normal value; 12. blood routine: hb ≥ 80g / l, anc ≥ 1.0 × 109 / l, plt ≥ 40 × 109 / l; 13. coagulation function: no bleeding tendency; 14. informed and voluntarily participated in the study and signed informed consent. exclusion criteria: 1. currently in the process of other clinical trials within recently four weeks; 2. previous abdominal radiotherapy and liver transplantation; 3. patients with severe chronic diseases of heart, kidney, liver and other important organs; 4. pregnant or lactating women; 5. suspected or indeed drug abusers, drug abusers and alcoholics; 6. allergic to lenvatinib or other treatments. 7. severe mental or nervous system disorders affecting informed consent and / or expression or observation of adverse reaction

Keywords: hepatocellular carcinoma intensity-modulated radiotherapy portal vein thrombosis lymph node metastasis lenvatinib